Synergistic whitening composition, application thereof and cosmetics

Abstract

The invention belongs to the technical field of cosmetics, and provides a synergistic whitening composition, application thereof and cosmetics, the synergistic whitening composition comprises ellagic acid and tetrahydromagnolol, and the mass ratio of the ellagic acid to the tetrahydromagnolol is 50: 1-1: 10. In the composition provided by the invention, the ellagic acid and the tetrahydromagnolol have a synergistic whitening effect, and in the aspect of inhibiting melanogenesis, the effect of the composition is obviously greater than the sum of the effects of independently using the ellagic acid and independently using the tetrahydromagnolol.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a synergistic whitening composition, its uses, and cosmetics. Background Technology

[0002] Chinese consumers have a persistent demand for skin whitening products, resulting in a wide variety of products and technologies on the market. However, many of these whitening products contain resorcinol-based active ingredients, which are often quite irritating. As people's living standards improve, their demands for quality of life also increase, leading to a growing preference for cosmetics using various natural plant extracts as whitening active ingredients. However, the classic plant extract glycyrrhizin is expensive, so it is added in very small quantities to products, making it difficult to achieve a truly whitening effect.

[0003] Ellagic acid is a natural polyphenol found in various fruits. It inhibits tyrosinase activity, blocks melanin production, and has a whitening and spot-fading effect. It is also one of the effective whitening ingredients recognized by dermatology.

[0004] Tetrahydromagnoliol is a whitening ingredient created through natural pathways and artificial synthesis, modeled on the natural component (magnoliol) in the bark of Magnolia officinalis.

[0005] This invention investigated the melanin-inhibiting effects of ellagic acid and tetrahydromagnoliol on human melanocytes, and found that a specific combination of ellagic acid and tetrahydromagnoliol has a good synergistic effect within a specific ratio range, thereby reducing the dosage of both and thus achieving cost reduction and efficiency improvement, while reducing possible adverse reactions. Summary of the Invention

[0006] In view of the shortcomings of the existing technology, the purpose of this invention is to provide a synergistic whitening composition, its uses and cosmetics, which utilizes the reasonable ratio of ellagic acid and tetrahydromagnoliol to produce synergistic whitening effects, and can reduce the amount of both used in the product, thereby saving costs while achieving better whitening effects.

[0007] In a first aspect, this application provides a synergistic whitening composition comprising ellagic acid and tetrahydromagnoliol, wherein the mass ratio of ellagic acid to tetrahydromagnoliol is 50:1 to 1:10.

[0008] In some embodiments, the mass ratio of ellagic acid to tetrahydromagnoliol is 10:1 to 1:1.

[0009] In some embodiments, the mass ratio of ellagic acid to tetrahydromagnoliol is 5:1 to 2:1.

[0010] In some embodiments, the mass ratio of ellagic acid to tetrahydromagnoliol is 1:1.

[0011] Secondly, this application provides the use of the aforementioned synergistic whitening composition in the preparation of cosmetics.

[0012] In some embodiments, the whitening composition synergistically inhibits melanin production.

[0013] In some embodiments, the cosmetic includes at least one of serum, gel, lotion, foundation, or cream.

[0014] Thirdly, this application provides a cosmetic product comprising the synergistic whitening composition described in any one of the above embodiments.

[0015] In some embodiments, the ellagic acid concentration in the cosmetic is 0.01 wt% to 0.5 wt%.

[0016] In some embodiments, the tetrahydromagnoliol in the cosmetic has a mass percentage concentration of 0.01 wt% to 0.5 wt%.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] Compared to existing technologies, this invention provides a composition with synergistic whitening effects, comprising ellagic acid and tetrahydromagnoliol in specific mass ratios. In the combination provided by this invention, ellagic acid and tetrahydromagnoliol exhibit synergistic whitening effects; in inhibiting melanin production, the composition's efficacy is significantly greater than the sum of the efficacies of using ellagic acid alone or using tetrahydromagnoliol alone. Attached Figure Description

[0019] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings:

[0020] Figure 1 The graphs show the melanin content test results of the blank control group, positive control group, comparative examples 1, 8 and 1 in this application.

[0021] Figure 1 In the figures: a is the blank control group, b is the positive control group, c is comparative example 1, d is comparative example 8, and e is example 1. The scale bar is 50 μm. Detailed Implementation

[0022] The present invention will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present invention, but do not limit the invention in any way. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention. These all fall within the scope of protection of the present invention.

[0023] Examples 1-7, Comparative Examples 1-12

[0024] The raw material composition of the synergistic whitening compositions of Examples 1-7 and Comparative Examples 11-12 in this invention is shown in Table 1. Meanwhile, as a single-factor control experiment, Comparative Examples 1-10 were designed, and the raw material composition is also shown in Table 1.

[0025] The melanin-inhibiting effects of the products obtained in Examples 1-7 and Comparative Examples 1-12 were tested, and the specific methods were as follows:

[0026] Testing system: The cells used were melanocytes, batch number: MC25021302, provided by Guangdong Boxi Shaanxi Branch.

[0027] Main reagents: M-254 culture medium (Guangdong Boxi Shaanxi Branch), PBS (Solepro), L-DOPA (Sigma), BCA kit (Beyotime), MTT (Sigma), DMSO (Sigma), silver staining kit (Solepro), paraformaldehyde (Biosharp).

[0028] Main equipment: CO2 incubator (Thermo, 1501), laminar flow hood (Sujing Antai, SW-CJ-2F), microplate reader (BioTek, Epoch), upright microscope (Olympus, BX53).

[0029] Cytotoxicity test methods:

[0030] 1. Cell seeding: After the cells have been revived, when the plating rate reaches about 60%, seed the cells into 96-well plates and incubate overnight in a CO2 incubator (37℃, 5v / v% CO2).

[0031] 2. Experimental Groups: The experiment included a blank control group, a positive control group, comparative example groups (Comparative Example 1 and Comparative Example 8), and an example group. In the example group, seven concentration gradients were set up (corresponding to Examples 1-7), with three replicate wells for each concentration gradient.

[0032] 3. Solution preparation: Prepare working solutions of different concentrations according to the test concentration setting table.

[0033] 4. The cytotoxicity test results of ellagic acid and tetrahydromagnoliol are shown in Table 2 and Table 3, respectively.

[0034] Methods for testing melanin content:

[0035] 1. Cell seeding: After cell resuscitation, when the cell plating rate reaches about 60%, seed the cells into 6-well plates and incubate overnight in a CO2 incubator (37℃, 5v / v% CO2).

[0036] 2. Solution preparation: Prepare the working solution of the test substance according to the test group. The positive control is 42.67 ppm kojic acid.

[0037] 3. Drug administration: According to the test groups, when the cell deposition rate in the 6-well plate reaches 40%–60%, drug administration is performed in groups, with 3 replicates per group. 2 mL of culture medium is added to each well of the blank control group, 2 mL of culture medium containing kojic acid is added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of the test sample is added to each well of the sample group. After drug administration, the 6-well plate is placed in a CO2 incubator (37℃, 5v / v% CO2) and incubated for 72 h. After 72 h, the medium is discarded, and the plate is washed once with PBS.

[0038] 4. Melanin content test: After cell culture, fix with 4wt% paraformaldehyde solution, stain according to the silver staining kit instructions, and photograph under a microscope. Figure 1 As shown in a, b, c, d, and e, red represents stained melanocytes, and black represents secreted melanin. In the blank control group, the melanin production was the highest. The melanin production in Comparative Example 1 and Comparative Example 8 was higher than that in Example 1.

[0039] 5. Inhibition rate calculation: Inhibition rate (%) = (blank control group - sample group) / blank control group × 100%.

[0040] Synergistic effect assessment method: Bliss independence method

[0041] In the Bliss model, the theoretical joint inhibition rate is: E A+B =E A +E B -E A *E B ,

[0042] If the actual combined inhibition rate is greater than the theoretical combined inhibition rate, then components A and B are determined to have a synergistic effect.

[0043] Results of melanin inhibition tests in Comparative Examples 1-12 and Examples 1-7

[0044]

[0045] Table 2 Results of Ellagic Acid Cytotoxicity Test

[0046]

[0047] Table 3 Results of tetrahydromagnoliol cytotoxicity test

[0048]

[0049] The E theory of Example 1 was calculated from the data of Comparative Examples 1 and 8; the E theory of Example 2 was calculated from the data of Comparative Examples 1 and 9; the E theory of Example 3 was calculated from the data of Comparative Examples 2 and 8; the E theory of Example 4 was calculated from the data of Comparative Examples 3 and 8; the E theory of Example 5 was calculated from the data of Comparative Examples 4 and 8; the E theory of Example 6 was calculated from the data of Comparative Examples 5 and 8; and the E theory of Example 7 was calculated from the data of Comparative Examples 6 and 8.

[0050] Comparative Examples 1–10 were single-component administrations, and E-theory was not calculated.

[0051] The E-theory of Comparative Example 11 was calculated from the data of Comparative Example 1 and Comparative Example 10, and the E-theory of Comparative Example 12 was calculated from the data of Comparative Example 7 and Comparative Example 8.

[0052] Comparing the theoretical E and actual E of Examples 1-7 and Comparative Examples 11-12, a synergistic determination is made:

[0053] If actual efficiency (E) > theoretical efficiency (E), then efficiency will be increased.

[0054] If Eactual < Etheoretical, then it is antagonistic;

[0055] If Eactual = Etheoretical, it is an addition.

[0056] The test results and synergistic determination of Examples 1-7 and Comparative Examples 1-12 are shown in Table 1. In Example 1, the theoretical E of 1 ppm ellagic acid and 0.2 ppm tetrahydromagnoliol is 59.5%, and the actual E of Example 1 is 73.00%. Since the actual E is greater than the theoretical E, it proves that ellagic acid and tetrahydromagnoliol have a synergistic effect in melanin inhibition at a ratio of 5:1.

[0057] Similarly, the actual values ​​of E in Examples 2 to 7 are all greater than the theoretical values ​​of E, indicating that when the mass ratio of ellagic acid to tetrahydromagnoliol is in the range of 50:1 to 1:10, ellagic acid and tetrahydromagnoliol have a synergistic effect in inhibiting melanin.

[0058] In contrast, the actual E in comparative examples 11–12 was slightly larger than the theoretical E, indicating that within the ratio range of comparative examples 11–12, ellagic acid and tetrahydromagnoliol did not have a synergistic effect in inhibiting melanin.

[0059] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A synergistic whitening composition, characterized in that, It includes ellagic acid and tetrahydromagnoliol, wherein the mass ratio of ellagic acid to tetrahydromagnoliol is 50:1 to 1:

10.

2. The synergistic whitening composition according to claim 1, characterized in that, The mass ratio of ellagic acid to tetrahydromagnoliol is 10:1 to 1:

1.

3. The synergistic whitening composition according to claim 2, characterized in that, The mass ratio of ellagic acid to tetrahydromagnoliol is 5:1 to 2:

1.

4. The synergistic whitening composition according to claim 3, characterized in that, The mass ratio of ellagic acid to tetrahydromagnoliol is 1:

1.

5. Use of the synergistic whitening composition according to any one of claims 1 to 4 in the preparation of cosmetics.

6. The use according to claim 5, characterized in that, The synergistic whitening composition can synergistically inhibit melanin production.

7. The use according to claim 5, characterized in that, The cosmetics include at least one of serum, gel, lotion, foundation, or cream.

8. A cosmetic product, characterized in that, Includes the synergistic whitening composition according to any one of claims 1 to 4.

9. The cosmetic product according to claim 8, characterized in that, The ellagic acid in the cosmetic has a mass percentage concentration of 0.01 wt% to 0.5 wt%.

10. The cosmetic product according to claim 8, characterized in that, The tetrahydromagnoliol in the cosmetic has a mass percentage concentration of 0.01 wt% to 0.5 wt%.

Images